Aarhus, Denmark — June 12, 2008 — Today, CLC bio released their new Next Generation Sequencing (NGS) solution, CLC Genomics Workbench, which incorporates cutting-edge technology and algorithms, while also supporting and integrating with the rest of a typical NGS workflow.
CLC Genomics Workbench is the first comprehensive analysis package which can analyze and visualize data from all the major NGS platforms,...

Services to accelerate programs from biological target to first-in-man use Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics,
screening, early ADMET and preclinical development capabilities to speed up
partnerâ€™s and clientâ€™s small molecules programs from biological target to firstin-
man use.
According to Serge Petit,...

Aarhus Denmark, July 3rd, 2008 â€“ Beijing Genomics Institute (BGI) has signed a global site license agreement for CLC bio’s Next Generation Sequencing solution, CLC Genomics Workbench. The site license covers all researchers at all BGI sites, both inside and outside of China.
Head of Bioinformatics Division at BGI, Ruiqiang Li states, â€œWe have chosen CLC Genomics Workbench as our platform for analyzing...

Aarhus Denmark — July 10, 2008 — On July 1st, CLC bio moved their Danish headquarters to a newly built office building in the Katrinebjerg area – a fast growing Danish ICT community which also features high-tech companies Google, VMware, and B&O, to name a few – as well as the University of Aarhus and the new interdisciplinary nanoscience center, which is currently under construction.
CEO at...

Boston, USA — April 29, 2008 — Today at the Bio-IT World Conference & Expo in Boston, USA, CLC bio announced collaboration with Microsoft Corp. on integrating CLC bio’s extensive bioinformatics solutions with Microsoft’s software platform, for the benefit of companies, corporations, and institutions in the biotech, pharmaceutical, and life science sectors. CLC bio has already added support for...

Hamburg, Germany | Oxford, UK- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that InterMune, Inc., has signed a second drug discovery contract with Evotec.
Evotec will support InterMune’s research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and ADMET to further...